[go: up one dir, main page]

AR056574A1 - Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso - Google Patents

Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Info

Publication number
AR056574A1
AR056574A1 ARP060104439A ARP060104439A AR056574A1 AR 056574 A1 AR056574 A1 AR 056574A1 AR P060104439 A ARP060104439 A AR P060104439A AR P060104439 A ARP060104439 A AR P060104439A AR 056574 A1 AR056574 A1 AR 056574A1
Authority
AR
Argentina
Prior art keywords
compounds
alkyl
compositions containing
use procedures
pirazol derivatives
Prior art date
Application number
ARP060104439A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR056574A1 publication Critical patent/AR056574A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos son utiles para tratar la diabetes mellitus de tipo 2 y afecciones relacionadas. Se incluyen también composiciones farmacéuticas y procedimientos de tratamiento. Reivindicacion 1: Un compuesto de formula (1) o una sal o solvato farmacéuticamente aceptable del mismo, en la que: R1 representa alquilo C1-6; R2 representa halo, alquilo C1-3 u O-alquilo C1-3 y R3 representa alquilo C1-6.
ARP060104439A 2005-10-19 2006-10-09 Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso AR056574A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72817705P 2005-10-19 2005-10-19

Publications (1)

Publication Number Publication Date
AR056574A1 true AR056574A1 (es) 2007-10-10

Family

ID=37603075

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104439A AR056574A1 (es) 2005-10-19 2006-10-09 Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Country Status (14)

Country Link
US (1) US20070088070A1 (es)
EP (1) EP1940799A1 (es)
KR (1) KR20080058416A (es)
CN (1) CN101291912A (es)
AR (1) AR056574A1 (es)
AU (1) AU2006304485A1 (es)
CA (1) CA2624532A1 (es)
DO (1) DOP2006000231A (es)
IL (1) IL190477A0 (es)
NO (1) NO20082256L (es)
PE (1) PE20070503A1 (es)
RU (1) RU2008119496A (es)
TW (1) TW200745044A (es)
WO (1) WO2007047676A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030318D1 (de) * 2003-01-27 2011-01-13 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
ATE395338T1 (de) * 2004-06-04 2008-05-15 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
EP1773330B1 (en) 2004-07-22 2010-05-26 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
AU2006276072A1 (en) * 2005-07-26 2007-02-08 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
US8143284B2 (en) 2006-10-05 2012-03-27 Abbott Laboratories Poly(ADP-ribose)polymerase inhibitors
JP2011520897A (ja) 2008-05-16 2011-07-21 シェーリング コーポレイション グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法
US8470773B2 (en) 2009-06-12 2013-06-25 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
PT2673260T (pt) 2011-02-08 2016-10-24 Pfizer Modulador do recetor de glucagon
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9493439B1 (en) * 2014-04-07 2016-11-15 University Of Kentucky Research Foundation Proteasome inhibitors
KR102708864B1 (ko) 2016-08-30 2024-09-25 리제너론 파마슈티칼스 인코포레이티드 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
JP7781519B2 (ja) 2017-08-22 2025-12-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030318D1 (de) * 2003-01-27 2011-01-13 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
ATE395338T1 (de) * 2004-06-04 2008-05-15 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren

Also Published As

Publication number Publication date
NO20082256L (no) 2008-07-15
IL190477A0 (en) 2008-11-03
US20070088070A1 (en) 2007-04-19
WO2007047676A1 (en) 2007-04-26
CA2624532A1 (en) 2007-04-26
TW200745044A (en) 2007-12-16
KR20080058416A (ko) 2008-06-25
CN101291912A (zh) 2008-10-22
PE20070503A1 (es) 2007-06-14
EP1940799A1 (en) 2008-07-09
DOP2006000231A (es) 2007-05-31
AU2006304485A1 (en) 2007-04-26
RU2008119496A (ru) 2009-12-10

Similar Documents

Publication Publication Date Title
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
ECSP055867A (es) Derivados de pirrolopirimidina
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
AR055060A1 (es) Derivados de n-(piridin-2-il)-sulfonamida
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
NO20085077L (no) Nye forbindelser
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
ECSP066653A (es) Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
NO20081582L (no) Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY27979A1 (es) Indoles sustituidos en posición 2,4
DK1961734T3 (da) Aminforbindelse og anvendelse deraf til medicinske formål
NO20054787L (no) Indenderivater som farmasotiske midler

Legal Events

Date Code Title Description
FA Abandonment or withdrawal